MG
AGIO icon

Mather Group’s Agios Pharmaceuticals AGIO Stock Holding History

Mather Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-95
Closed -$3.81K – 664
2025
Q3 		$3.81K Buy
+95
New +$3.57K ﹤0.01% 1448
2025
Q2 		– Sell
-80
Closed -$2.34K – 636
2025
Q1 		$2.34K Buy
+80
New +$2.65K ﹤0.01% 1548
2024
Q3 		– Sell
-55
Closed -$1.61K – 1719
2024
Q2 		$1.61K Buy
+55
New +$1.99K ﹤0.01% 1941

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Mather Group's AGIO Position: Q4 2025 in Review

Mather Group sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 95 shares — an estimated $3.81K sold.

Mather Group first reported a position in AGIO in Q2 2024 and held it in 3 quarters. The position peaked at $3.81K in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Mather Group reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mather Group sold 95 Agios Pharmaceuticals shares in Q4 2025, an estimated $3.81K.
  • Mather Group first reported a position in Agios Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Mather Group's Agios Pharmaceuticals position peaked at $3.81K in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.